RxDoctor Payments Data

Ilia Itin, MD

Neurology · Cleveland, OHNPI 1386607281

Payments from drug & device makers

$71,379in general payments, 2019–2025

Across 24 payments — averaging $2974.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • H. Lundbeck A S$44K
  • Sunovion Pharmaceuticals Inc.$17K
  • Acorda Therapeutics, Inc$7K
  • Amneal Pharmaceuticals LLC$2K
  • Teva Pharmaceuticals USA, Inc.$217
  • Insightec,inc$198
  • plus $122 from 3 others

What the payments were for

  • Consulting fees$90%
  • Speaking & faculty fees$8,81890%
  • Food & beverage$7217%
  • Education$2172%

General payments by program year

19
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$71,379 in reported general payments places this provider in the 80th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$117,953
Medicare patients
439
Services billed
1,390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate224$1,166,427
IngrezzaValbenazine Tosylate83$663,710
AustedoDeutetrabenazine64$587,396
RytaryCarbidopa/Levodopa93$158,253
GocovriAmantadine Hcl17$48,092
Tetrabenazine16$43,679
Carbidopa-LevodopaCarbidopa/Levodopa894$31,298
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone100$29,913
Carbidopa31$26,078
Rivastigmine57$9,787
Mirtazapine214$8,347
Carbidopa-Levodopa ErCarbidopa/Levodopa70$8,062
Rasagiline Mesylate32$6,533
Ropinirole ErRopinirole Hcl13$5,423
Entacapone24$4,771

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$31$1,166,427224 claims
Teva Pharmaceuticals USA, Inc.Austedo$217$587,39664 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$1,905$158,956111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 702 neurology providers in Ohio.

Other neurology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →